Abstract 1808P
Background
In CABASTY trial (NCT02961257), CBZ 16 mg/m2 q2w + G-CSF significantly reduced grade ≥3 neutropenia and/or neutropenic complications vs CBZ 25 mg/m2 q3w + G-CSF with comparable overall survival (OS) benefit in older and heavily pretreated patients (pts) with mCRPC (Oudard et al. ESMO 2022). Here, we report changes in HRQL in both arms during therapy.
Methods
The Functional Assessment Cancer Therapy-Prostate (FACT-P) questionnaire was collected at each visit and analyzed in all pts exposed to CBZ with evaluable HRQL at baseline and post-baseline. Higher values indicated better HRQL. Changes of ≥10 points in FACT-P total score and ≥2 points in Prostate Cancer Subscale (PCS)-pain score, confirmed by 2 consecutive evaluations were judged clinically meaningful.
Results
196 pts (median age, 74.6 yrs; ≥75 yrs, 49%; G8 <14, 20%; vulnerable or frail per SIOG guidelines, 30.1%; moderate to severe pain, 18%) previously treated with docetaxel and novel hormonal therapies (median 3 lines) were randomized to CBZ q3w (n=97) or q2w (n=99) + G-CSF. Median treatment duration was 19.0 and 20.1 weeks with CBZ q3w and q2w, respectively. HRQL was evaluable in 88 (90.7%) and 96 (97.0%) pts with CBZ q3w and q2w. PCS-pain improved in 35.2% vs 38.5% (CBZ q3w vs q2w). The probability of not having PCS-pain deterioration during treatment was 81.8% vs 75.0% with CBZ q3w vs q2w (HR=1.5 [95% CI, 0.80-2.9], p=0.2). Total FACT-P score improved from baseline in 17.0% vs 13.5% of pts with CBZ q3w vs q2w, respectively. FACT-P score was either stable or improved from baseline in 75.0% vs 74.0% of pts with CBZ q3w vs q2w. At 75% percentile, time to deterioration was 4.9 vs 3.3 months (HR: 1.2; p =0.57) with CBZ q3w vs q2w.
Conclusions
In this older and heavily pretreated mCRPC pts population, CBZ q3w and q2w + G-CSF similarly relieved pain and maintained or improved HRQL in 3 out of 4 pts with a comparable OS benefit. Since bi-weekly dosing induces less grade ≥3 neutropenia and/or neutropenic complications, it should be offered to pts unfit to receive the standard CBZ regimen.
Clinical trial identification
NCT02961257.
Editorial acknowledgement
Legal entity responsible for the study
ARTIC.
Funding
Sanofi.
Disclosure
S. Oudard: Financial Interests, Personal and Institutional, Advisory Board: Sanofi, Bayer, Janssen, AstraZeneca; Financial Interests, Personal, Advisory Board: Astellas, Pfizer. R. Ratta: Financial Interests, Personal, Invited Speaker: Ipsen, Astellas; Financial Interests, Personal, Advisory Board: Pfizer, Merck, BMS, AstraZeneca, Janssen. P. Barthelemy: Financial Interests, Personal, Advisory Board: BMS, MSD, Merck, Pfizer, Ipsen, Bayer, Janssen Cilag, Astellas, Novartis, Amgen, Gilead; Financial Interests, Personal, Invited Speaker: AstraZeneca, Seagen. A. Thiery-Vuillemin: Financial Interests, Personal, Advisory Board, & public speaking: Pfizer, AstraZeneca, Janssen, Ipsen, BMS; Financial Interests, Personal, Advisory Board: Sanofi, Novartis, Roche/Genentech, MSD, Astellas Pharma; Financial Interests, Personal, Full or part-time Employment, since 2023: BMS; Financial Interests, Institutional, Funding: Pfizer, Ipsen, Bayer; Financial Interests, Institutional, Local PI: Pfizer, AstraZeneca, Sanofi, JNJ, Novartis, Ipsen, Roche, BMS, MSD, Astellas Pharma, Excelixis, UNICANCER/GETUG, Incyte; Financial Interests, Steering Committee Member: AstraZeneca, Novartis, BMS; Non-Financial Interests, Member: ASCO, GETUG; Other, Other, Travel, Accommodations: Roche, MSD, JNJ, BMS, AstraZeneca, Pfizer, Astellas Pharma, Ipsen. K. Aldabbagh: Financial Interests, Personal, Advisory Board: Ipsen, Janssen, Novartis, Pfizer. C. Saldana: Financial Interests, Personal, Advisory Board: BMS, Ipsen, Pfizer, Bayer. G. Von Amsberg: Financial Interests, Personal, Advisory Board: Roche, BMS, Astellas, Sanofi, Janssen, MSD, Ipsen, Pfizer, AstraZeneca, Merck, Eisai. N. Houede: Financial Interests, Personal, Advisory Board: Astellas, AstraZeneca, BMS, Merck, Pfizer, MSD, Janssen. D. Vernerey: Financial Interests, Personal, Advisory Board: SAS Novis, CellProtera SAS, Apmonia Therapeutics, Incyte, Veracyte SAS, INVECTYS, Novartis. C. Helissey: Financial Interests, Personal, Advisory Board: Janssen, Roche, Sanofi, Astellas, AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1783P - PROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Efficacy results from the pilot phase
Presenter: Jose Arranz Arija
Session: Poster session 14
1785P - Changes in bone mineral density, trabecular bone score and body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide plus/minus zoledronic acid: The BonEnza study
Presenter: Alberto Dalla Volta
Session: Poster session 14
1787P - Prostate specific membrane antigen positron emission tomography (PSMA PET)-directed clinical outcomes in metastatic hormone-sensitive prostate cancer (mHSPC): Implications for the STAMPEDE2 trial design
Presenter: Hoda Abdel-Aty
Session: Poster session 14
1789P - Low- and high-volume disease in mHSPC: From CHAARTED to PSMA PET
Presenter: Lena Unterrainer
Session: Poster session 14
1790P - Utilisation rates of treatment intensification for metastatic hormone sensitive prostate cancer (mHSPC) in England, UK
Presenter: Joanna Dodkins
Session: Poster session 14
1791P - Molecular profiling and prognostic relevance of low PTEN expression in metastatic hormone-sensitive prostate cancer patients
Presenter: Marta Garcia De Herreros
Session: Poster session 14
1792P - Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 14